

CITATION REPORT

List of articles citing

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

DOI: 10.1007/s00262-006-0272-1

Cancer Immunology, Immunotherapy, 2007, 56, 739-45.

Source: <https://exaly.com/paper-pdf/43078238/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
380	DNA vaccines for cervical cancer: from bench to bedside. 2007 , 39, 679-89		57
379	CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. 2007 , 178, 6840-8		94
378	Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. 2007 , 37, 2983-90		58
377	An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. 2007 , 247, 95-102		11
376	Inhibitory costimulation and anti-tumor immunity. 2007 , 17, 288-98		23
375	Interleukin-4 impairs granzyme-mediated cytotoxicity of Simian virus 40 large tumor antigen-specific CTL in BALB/c mice. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1625-36	7.4	9
374	Immunity, ageing and cancer. 2008 , 5, 11		108
373	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. 2008 , 113, 2139-45		70
372	Immunotherapy of malignant brain tumors. 2008 , 222, 70-100		73
371	The impact of T-cell immunity on ovarian cancer outcomes. 2008 , 222, 101-16		124
370	Antigen-specific immunotherapy of cervical and ovarian cancer. 2008 , 222, 43-69		54
369	How tumours escape mass destruction. 2008 , 27, 5894-903		145
368	The Janus face of dendritic cells in cancer. 2008 , 27, 5920-31		72
367	Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. 2008 , 124, 277-93		45
366	PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. 2008 , 129, 132-44		55
365	New dimensions in tumor immunology: what does 3D culture reveal?. 2008 , 14, 333-40		104
364	Therapeutic human papillomavirus vaccines: current clinical trials and future directions. 2008 , 8, 421-39		132

363	Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. 2008 , 14, 3044-51		563
362	Outlining the Gap Between Preclinical Models and Clinical Situation. 2008 , 31-54		
361	Subsets of myeloid-derived suppressor cells in tumor-bearing mice. 2008 , 181, 5791-802		1289
360	Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. 2008 , 7, 622-7		88
359	Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. 2008 , 111, 5359-70		99
358	PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. 2008 , 49, 2518-25		94
357	Different spectra of therapeutic vaccine development against HPV infections. 2009 , 5, 671-89		27
356	Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. 2009 , 183, 7898-908		55
355	Suppressing the suppressor: Role of immunosuppressive regulatory T cells in cancer surgery. 2009 , 145, 345-50		2
354	Immunotherapy: from basic research to clinical applications. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1129-36	7.4	1
353	Cytomegalovirus and human immunosenescence. 2009 , 19, 47-56		259
352	PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. 2009 , 23, 375-82		142
351	Neuron-interacting satellite glial cells in human trigeminal ganglia have an APC phenotype. 2009 , 183, 2456-61		58
350	Adenosine receptors and cancer. 2009 , 399-441		102
349	Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 1317-32	3.5	50
348	Immunosenescence and vaccination of the elderly II. New strategies to restore age-related immune impairment. 2009 , 56, 301-12		6
347	HPV and Therapeutic Vaccines: Where are We in 2010?. 2010 , 6, 81-103		31
346	DNA vaccination in oncology: current status, opportunities and perspectives. 2010 , 5, 218-25		3

345	Current status of immunological therapies for prostate cancer. 2010 , 20, 241-6	36
344	Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice. 2010 , 33, 136-45	32
343	Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. 2010 , 115, 2397-406	57
342	Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. 2010 , 116, 2484-93	211
341	Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression. 2010 , 58, 399-405	10
340	T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. 2010 , 362, 131-41	47
339	The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. 2010 , 116, 222-33	28
338	Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens. 2010 , 127, 1625-36	39
337	Immunosenescence and cancer. 2010 , 75, 165-72	98
336	Factors that may impact on immunosenescence: an appraisal. 2010 , 7, 7	88
335	The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with β radiation-induced T-cell lymphoblastic lymphomas. 2010 , 29, 5265-73	7
334	Unexpected acceleration of type 1 diabetes by transgenic expression of B7-H1 in NOD mouse peri-islet glia. 2010 , 59, 2588-96	15
333	Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression. 2010 , 185, 7340-8	39
332	Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease. 2010 , 184, 3554-61	11
331	Expression profiling of genes associated with regulatory functions of T-cell subsets in Marek's disease virus-infected chickens. 2010 , 39, 367-73	12
330	Immune responses to malignancies. 2010 , 125, S272-83	129
329	Immunosenescence and cancer. 2010 , 1, 20-26	8
328	Novel targeted therapeutics for metastatic castration-resistant prostate cancer. 2010 , 291, 1-13	62

327	Fighting cancers from within: augmenting tumor immunity with cytokine therapy. 2010 , 31, 356-63	32
326	Experimental and Applied Immunotherapy. 2011 ,	
325	Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade. 2011 , 42, 103	55
324	Stage dependent destructuration of neuro-endocrine-immune system components in lung cancer patients. 2011 , 65, 69-76	5
323	Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. 2011 , 35, 400-12	275
322	Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders. 2011 , 72, 1001-6	26
321	The suppressive tumor microenvironment: a challenge in cancer immunotherapy. 2011 , 8, 635-41	124
320	Cellular Immunotherapy for Malignant Brain Tumors. 2011 ,	
319	Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. 2011 , 17, 3322-9	104
318	Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. 2011 , 34, 297-306	81
317	[New treatment strategy for adult T-cell leukemia targeting for anti-tumor immunity and a longevity gene-encoded protein]. 2011 , 131, 1061-72	7
316	Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells. 2011 , 132, 340-7	42
315	Immune regulation in Chandipura virus infection: characterization of CD4+ T regulatory cells from infected mice. 2011 , 8, 259	8
314	CD4+ T cell response against a non-tumor antigen is unaffected in melanoma-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 145-51	7-4 2
313	Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 965-74	7-4 49
312	PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. 2011 , 128, 887-96	299
311	Immunotherapy for ovarian cancer: what's next?. 2011 , 29, 925-33	95
310	PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. 2011 , 71, 5111-22	113

309	Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. 2011 , 56, 118-24	67
308	Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V β V α T cells, CD8 ⁺ T cells, regulatory T cells, and dendritic cells. 2011 , 187, 1578-90	60
307	Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1. 2011 , 79, 1873-81	37
306	Reduced Tim-3 expression on human T-lymphotropic virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes in HTLV-I infection. 2011 , 203, 948-59	31
305	B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. 2012 , 189, 2338-47	39
304	Melanoma as a model tumour for immuno-oncology. 2012 , 23 Suppl 8, viii10-4	74
303	Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study. 2012 , 98, 751-755	134
302	Mechanisms of indirect acute lung injury: a novel role for the coinhibitory receptor, programmed death-1. 2012 , 255, 158-64	39
301	Programmed death 1 expression as a marker for immune and physiological dysfunction in the critically ill surgical patient. 2012 , 38, 117-22	38
300	Immunotherapy for melanoma. 2012 , 7, 51-68	
299	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. 2012 , 13, 459-65	833
298	siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. 2012 , 19, 959-66	44
297	Combination immunotherapy approaches. 2012 , 23 Suppl 8, viii41-6	103
296	Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls. 2012 , 12, 181-94	15
295	Perspectives on Therapeutic HPV Vaccines: Where Are We Now?. 2012 , 341-389	
294	The characteristic expression of B7-associated proteins in Langerhans cell sarcoma. 2012 , 114, 733-43	14
293	Immunopathogenesis and neurological manifestations associated to HTLV-1 infection. 2012 , 45, 545-52	21
292	Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8 ⁺ T cells. 2012 , 42, 662-71	13

291	Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 917-26	7.4	115
290	Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. 2012 , 22, 282-8		53
289	B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. 2013 , 7, 113-21		103
288	B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function. 2013 , 48, 1362-72		16
287	New therapeutic options in systemic treatment of advanced cutaneous melanoma. 2013 , 22, 181-90		11
286	Association of the costimulatory molecule gene polymorphisms and active cytomegalovirus infection in hematopoietic stem cell transplant patients. 2013 , 40, 5833-42		18
285	Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. 2013 , 1, 251-61		57
284	Autoimmune effector memory T cells: the bad and the good. 2013 , 57, 12-22		62
283	Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. 2013 , 190, 5620-8		81
282	Anti-PD-1 antibody significantly increases therapeutic efficacy of <i>Listeria monocytogenes</i> (Lm)-LLO immunotherapy. 2013 , 1, 15		43
281	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. 2013 , 9, 391-397		9
280	Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus. 2013 , 36, 63-9		17
279	[Immunological analogies between ovarian cancer and pregnancy]. 2013 , 42, 217-26		
278	Monoclonal antibodies in oncology therapeutics: present and future indications. 2013 , 13, 269-82		19
277	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. 2013 , 12, 1325-40		4
276	Methods to improve adoptive T-cell therapy for melanoma: IFN- γ enhances anticancer responses of cell products for infusion. 2013 , 133, 545-52		30
275	CD4 T cell responses in latent and chronic viral infections. <i>Frontiers in Immunology</i> , 2013 , 4, 105	8.4	17
274	Imbalance between circulating CD4+ regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure. 2013 , 33, 1517-26		26

273	Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. 2013 , 5, 1519-1526		13
272	[The immune system - how does anti-tumor immunity arise ?]. 2014 , 37 Suppl 4, 2-5		1
271	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. 2014 , 3, 151-65		9
270	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. 2014 , 24, 743-50		44 ⁰
269	PTEN functions as a melanoma tumor suppressor by promoting host immune response. 2014 , 33, 4632-42		69
268	PD-1 blockage delays murine squamous cell carcinoma development. 2014 , 35, 424-31		29
267	Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells. 2014 , 3, e956579		42
266	Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. <i>PLoS ONE</i> , 2014 , 9, e89561	3.7	4 ⁰
265	Cutaneous Hematopathology. 2014 ,		
264	Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. 2014 , 47, 612-7		32
263	Advances in Diagnosis and Management of Ovarian Cancer. 2014 ,		2
262	Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. 2014 , 142, 551-61		34
261	Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. 2014 , 92, 195-203		79
260	Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review. 2014 , 32, 113-9		13
259	Dendritic cell-mediated survival signals in EEMyc B-cell lymphoma depend on the transcription factor C/EBP β <i>Nature Communications</i> , 2014 , 5, 5057	17.4	14
258	In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. 2014 , 20, 2773-82		337
257	Immunosuppressive monocytes: possible homeostatic mechanism to restrain chronic intestinal inflammation. 2014 , 96, 377-89		13
256	Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration. 2014 , 55, 405-14		31

255	Combination immunotherapy with CTLA-4 and PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. 2015 , 3, 21	122
254	Autologous cellular vaccine overcomes cancer immunoeediting in a mouse model of myeloma. 2015 , 146, 33-49	5
253	Molecular biomarkers in gastric cancer. 2015 , 13, e19-29	26
252	TIGIT predominantly regulates the immune response via regulatory T cells. 2015 , 125, 4053-62	317
251	Notch Signaling Pathway Was Involved in Regulating Programmed Cell Death 1 Expression during Sepsis-Induced Immunosuppression. 2015 , 2015, 539841	19
250	T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?. 2015 , 14, 1492-1509	45
249	Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors. 2015 , 13, 161	19
248	Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. 2015 , 11, 997-1009	2
247	TLR4 mutant mice are protected from renal fibrosis and chronic kidney disease progression. 2015 , 3, e12558	60
246	Developments in T Cell Based Cancer Immunotherapies. <i>Cancer Drug Discovery and Development</i> , 2015 ,	0.3
245	Programmed death ligand-1 expression and memory T-cell generation in Coxiella burnetii infection. 2015 , 80, 1-6	1
244	IL-4-secreting secondary T follicular helper (Tfh) cells arise from memory T cells, not persisting Tfh cells, through a B cell-dependent mechanism. 2015 , 194, 2999-3010	39
243	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. 2015 , 14, 847-56	1248
242	Pembrolizumab for the treatment of melanoma. 2015 , 8, 515-27	2
241	PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. 2015 , 32, 212	67
240	Second-line therapies in metastatic urothelial carcinoma. 2015 , 29, 341-59, x	4
239	Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 817-29	7.4 142
238	Pembrolizumab versus Ipilimumab in Advanced Melanoma. 2015 , 372, 2521-32	3792

237	PDL1 expression is an independent prognostic factor in localized GIST. 2015 , 4, e1002729		51
236	Multiplying therapies and reducing toxicity in metastatic melanoma. 2015 , 16, 1014-8		9
235	-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. 2017 , 10, 101-112		43
234	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. 2016 , 2016, 9839685		15
233	Low Interferon Relative-Response to Cytomegalovirus Is Associated with Low Likelihood of Intrauterine Transmission of the Virus. <i>PLoS ONE</i> , 2016 , 11, e0147883	3-7	9
232	Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. 2016 , 16, 1-7		41
231	An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors. 2016 , 107, 108-19		44
230	Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. 2016 , 18, 1002-1011		114
229	A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. 2016 , 36, 313-320		3
228	Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. 2016 , 55, 428-41		29
227	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. 2016 , 6, 25952		29
226	Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. 2016 , 1, 75-81		7
225	IL-10 Induces T Cell Exhaustion During Transplantation of Virus Infected Hearts. 2016 , 38, 1171-81		5
224	Beyond the Oncogene Revolution: Four New Ways to Combat Cancer. 2016 , 81, 85-92		6
223	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. 2016 , 34, 347-54		43
222	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. 2016 , 15, 1746-56		37
221	Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. 2016 , 23, 142-8		93
220	Enhanced expression of PD-L1 in oral squamous cell carcinoma-derived CD11b(+)Gr-1(+) cells and its contribution to immunosuppressive activity. 2016 , 59, 20-29		15

219	Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS). 2016 , 14, 312	18
218	Targeting the PD-1/PD-L1 axis in the treatment of lung cancer. 2016 , 7, 17-27	
217	Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. 2016 , 5, e1181252	41
216	[Immunological aspects of ovarian cancer: Therapeutic perspectives]. 2016 , 45, 1020-1036	1
215	PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women: A Hospital-Based Observational Study. 2016 , 95, e3760	31
214	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. 2016 , 2, 46-54	527
213	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. 2016 , 76, 1578-90	308
212	Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. 2016 , 12, 1418-29	53
211	Cellular senescence and tumor promotion: Is aging the key?. 2016 , 1865, 155-67	48
210	Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. 2016 , 8, 593-603	109
209	PD-L1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 797-804	7-4 13
208	Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice. 2016 , 300, 9-17	11
207	PD-1 expression by canine T cells and functional effects of PD-1 blockade. 2017 , 15, 1487-1502	33
206	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. 2017 , 6, e1314424	69
205	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. 2017 , 28, 874-881	144
204	Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. 2017 , 38, 823-834	48
203	Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. 2017 , 4, 169-173	25
202	The added value of type I interferons to cytotoxic treatments of cancer. 2017 , 36, 89-97	13

201	Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. 2017 , 44, 403-414		66
200	The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 765-776	7-4	24
199	Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?. 2017 , 9, 99-108		18
198	Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. 2017 , 13, 1049-1060		47
197	GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC. 2017 , 6, e1353860		18
196	Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. 2017 , 68, 103-111		47
195	Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors. 2017 , 29, 474-483		8
194	Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. 2017 , 152, 472-483		17
193	Ageing and latent CMV infection impact on maturation, differentiation and exhaustion profiles of T-cell receptor gammadelta T-cells. 2017 , 7, 5509		26
192	Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. 2017 , 599, 28-35		33
191	The safety of anti PD-1 therapeutics for the treatment of melanoma. 2017 , 16, 41-53		13
190	Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. 2017 , 52, 93-99		27
189	Recent advances in understanding Epstein-Barr virus. 2017 , 6, 386		40
188	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017 , 8, 41641-41669	3-3	13
187	Current status and future prospects of the strategy of combining CAR-T with PD-1 blockade for antitumor therapy (Review). 2018 , 17, 2083-2088		9
186	Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. 2018 , 9, 646-651		3
185	Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy. 2018 , 18, 3250-3258		180
184	Dosimetry Prediction for Clinical Translation of Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. 2018 , 8, 633		29

183	Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. 2018 , 4, 1-7		4
182	Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer. 2018 , 41, 638-642		24
181	Early Phase Cancer Immunotherapy. 2018 ,		1
180	Pharmacokinetics and Pharmacodynamics of Immunotherapy. 2018 , 29-67		2
179	Using the Spleen as an Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with -PD-L1. 2018 , 2018, 8694397		14
178	HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. 2018 , 19,		50
177	Glycans as Key Checkpoints of T Cell Activity and Function. <i>Frontiers in Immunology</i> , 2018 , 9, 2754	8.4	59
176	Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. 2018 , 19,		19
175	[Immunological foundations of modern (tumor) immunotherapy]. 2018 , 39, 492-497		
174	Human Monocytic Suppressive Cells Promote Replication of and Alter Stability of Generated Granulomas. <i>Frontiers in Immunology</i> , 2018 , 9, 2417	8.4	19
173	PD-1 blockade potentially enhances adoptive cytotoxic T cell potency in a human acute myeloid leukaemia animal model. 2018 , 23, 740-746		8
172	PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. 2018 , 9, 2938-2945		78
171	Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. 2018 , 101, 114-122		32
170	Dendritic cells cross-talk with tumour antigen-specific CD8 T cells, V β 17 cells and V β 4NKT cells in patients with glioblastoma multiforme and in healthy donors. 2018 , 194, 54-66		5
169	Myeloid-Derived Suppressor Cells (MDSCs) in Aged Mice: Focus on Inflammation. 2018 , 1-21		
168	Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. 2018 , 17, 7		46
167	Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. 2018 , 11, 43		39
166	Therapeutic outcomes in non-small cell lung cancer with mutations: a single institution, retrospective cohort study. 2019 , 8, 258-267		7

165	Cancer Immunoediting and Hijacking of the Immune System. 2019 , 117-139		
164	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. <i>Frontiers in Immunology</i> , 2019 , 10, 1337	8.4	63
163	NK Cell-Fc Receptors Advance Tumor Immunotherapy. 2019 , 8,		11
162	Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. 2019 , 7,		61
161	Molecular and Cell Biology of Cancer. 2019 ,		1
160	PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma. 2019 , 19, 503		12
159	Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. 2019 , 27, 2411-2425.e9		144
158	Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. 2019 , 39, 284-300		9
157	Immunohistochemistry. 2019 , 53-91		0
156	The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2019 , 10, 653	8.4	25
155	Immunologische Grundlagen moderner (Tumor-)Immuntherapie. 2019 , 14, 8-13		
154	Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. 2019 , 9, 6136		71
153	Camptothecin Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells. 2019 , 6,		11
152	Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis. 2019 , 98, e14006		16
151	Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR-PD-L1 NSCLC to Anti-PD-1 Immunotherapy. 2019 , 7, 990-1000		13
150	PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials. 2019 , 17, e618-e626		8
149	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. 2019 , 7, 353		55
148	The Possible Role of PD-1 Protein in -Mediated Immunomodulation and Cancer Treatment. 2019 , 18, 1534735419880275		3

147	Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D. 2019 , 26, 213-218	14
146	Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity. 2019 , 11, 1876-1885	74
145	Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy. 2019 , 293, 104-112	35
144	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. 2019 , 12, 7	68
143	Vascularized composite allograft rejection is delayed by infusion of IFN- γ -conditioned BMSCs through upregulating PD-L1. 2019 , 376, 211-220	2
142	Chimeric tumor modeling reveals role of partial PDL1 expression in resistance to virally induced immunotherapy. 2019 , 7, 11	3
141	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. 2019 , 40, 17-65	209
140	Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. 2019 , 35, 251-256	17
139	Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations. 2020 , 22, 1276-1287	4
138	Correlation of MET and PD-L1 Expression in Malignant Melanoma. <i>Cancers</i> , 2020 , 12,	6.6 3
137	Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group. 2020 , 112, 524-534	1
136	Prognostic Role of Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma. <i>Life</i> , 2020 , 10,	3 1
135	Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines. 2020 , 2020, 8910183	5
134	Targeting the immune milieu in gastrointestinal cancers. 2020 , 55, 909-926	2
133	Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility. 2020 , 12, 153-163	1
132	Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma. 2020 , 8,	14
131	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. 2020 , 8,	18
130	Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice. 2020 , 19, 3595-3607	8

129	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. 2020 , 127, 109996			14
128	Relationship between IL-10 and PD-L1 in esophageal carcinoma tissues and IL-10 down-regulates PD-L1 expression via Met signaling pathway. 2020 , 11, 337-355			3
127	Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6		4
126	Low expressions of PD-L1 and CTLA-4 by induced CD4CD25 Foxp3 Tregs in patients with SLE and their correlation with the disease activity. 2020 , 133, 155119			6
125	Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. 2020 , 10, 9705			22
124	Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas. 2020 , 10, 9077			23
123	Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis. 2020 , 16, 597-612			8
122	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. <i>Journal of Biosciences</i> , 2020 , 45, 1	2.3		11
121	Exosomes: Effectual players in rheumatoid arthritis. 2020 , 19, 102511			32
120	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. 2020 ,			14
119	Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse. 2020 , 74, e13594			3
118	Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer. 2020 , 20, 401-411			6
117	Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?. <i>Frontiers in Immunology</i> , 2020 , 11, 275	8.4		56
116	Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy. 2020 , 242, 119933			45
115	Epigenetic Silencing of Ubiquitin Specific Protease 4 by Snail1 Contributes to Macrophage-Dependent Inflammation and Therapeutic Resistance in Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6		9
114	Inclusion of PD-L1 into a recombinant profilin antigen enhances immunity against <i>Babesia microti</i> in a murine model. 2020 , 11, 101446			2
113	Upregulation of TIGIT and PD-1 in Colorectal Cancer with Mismatch-repair Deficiency. 2021 , 50, 338-355			8
112	Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. 2021 , 147, 459-468			2

111	The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. 2021 , 13, 757-764		
110	Detection of Programmed Cell Death Ligand 1 Expression in Lung Cancer Clinical Samples by an Automated Immunohistochemistry System. 2021 , 2279, 35-47		1
109	Phenylboronic acid-based core-shell drug delivery platform clasping 1,3-dicarbonyl compounds by a coordinate interaction. 2021 , 9, 6851-6864		1
108	DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma. 2021 , 17, 3158-3172		3
107	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. 2021 , 53, 141-156		25
106	The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?. 2021 , 51, 204-213		2
105	Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis. 2020 , 10, 572203		3
104	Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. 2021 , 33, e12943		0
103	Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy. 2021 , 10, e2002104		10
102	Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective. 2021 , 33, 116038		1
101	Immune Milieu Established by Postpartum Liver Involution Promotes Breast Cancer Liver Metastasis. <i>Cancers</i> , 2021 , 13,	6.6	2
100	Gene expression patterns associated with tumor-infiltrating CD4+ and CD8+ T cells in invasive breast carcinomas. 2021 , 82, 279-287		1
99	Fetomaternal Immune Tolerance: Crucial Mechanisms of Tolerance for Successful Pregnancy in Humans. 2021 , 1-18		3
98	Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. 2021 , 93, 107403		6
97	Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis. 2021 , 100, e25318		1
96	Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. 2021 , 20, 1295-1304		0
95	Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. 2021 , 13,		3
94	Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia. 2021 , 21, 328-337.e1		0

93	Myelodysplastic syndrome and immunotherapy novel to next in-line treatments. 2021 , 17, 2602-2616	1
92	Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. 2021 , 17, 2243-2256	10
91	Prospects and Challenges for T Cell-Based Therapies of HCC. 2021 , 10,	2
90	A theoretical model for an electromagnetic antenna in induction of virtual T cells. 2021 , 10, 1	
89	Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. 2021 ,	6
88	Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial. 2021 ,	1
87	Evolving therapeutic strategies for advanced hepatocellular carcinoma. 2021 , 22, 2495-2506	
86	Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies. 2021 , 10,	2
85	Immune normalization strategy against suboptimal health status: safe and efficacious therapy using mixed-natural killer cells. 2021 , 13, 20131-20148	2
84	Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. 2021 ,	0
83	Deciphering PD1 activation mechanism from molecular docking and molecular dynamic simulations.	
82	CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway. 2021 , 9, 1441	0
81	Human V β V δ T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells. 2021 , 573, 132-139	2
80	Targeted photodynamic immunotherapy. 2022 , 463-481	
79	Negative Regulators in Cancer Immunology and Immunotherapy. 2011 , 229-249	1
78	The Role of Exhaustion in Tumor-Induced T-Cell Dysfunction in Cancer. 2020 , 117-132	3
77	The Role of Exhaustion in Tumor-Induced T Cell Dysfunction in Cancer. 2015 , 61-75	2
76	Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 501-510	3-5 3

75	Silencing Signal Transducer and Activator of Transcription 3 (STAT3) and Use of Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody Induces Immune Response and Anti-Tumor Activity. <i>Medical Science Monitor</i> , 2020 , 26, e915854	3.2	3
74	Tim-3 expression defines regulatory T cells in human tumors. <i>PLoS ONE</i> , 2013 , 8, e58006	3.7	110
73	miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. <i>Oncotarget</i> , 2016 , 7, 53735-53750	3.3	80
72	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , 2017 , 8, 13320-13328	3.3	50
71	Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017 , 8, 30175-30189	3.3	53
70	Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. <i>Oncotarget</i> , 2017 , 8, 46020-46033	3.3	23
69	Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. <i>Oncotarget</i> , 2015 , 6, 11139-49	3.3	72
68	Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2015 , 7, 462-70	2.6	88
67	Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist. <i>ImmunoHorizons</i> , 2020 , 4, 837-850	2.7	7
66	The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. <i>Gut and Liver</i> , 2014 , 8, 186-195	4.8	24
65	Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4 PD-1 and LAG-3. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021 ,	1.9	1
64	Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma. <i>Bioengineered</i> , 2021 , 12, 9520-9530	5.7	0
63	Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy. <i>Cancer Medicine</i> , 2021 , 10, 8071-8078	4.8	1
62	Modification of Dendritic Cells to Enhance Cancer Vaccine Potency. 2009 , 133-157		
61	Antigen-targeted, synthetic vaccines for metastatic cancer. 2011 , 103-125		
60	Principles of tumor immunology. 2013 , 925-934		
59	Targeted Molecular Therapy for Patients with Ovarian Cancer. 2014 , 199-222		
58	What Is the Future of Immunotherapy in Ovarian Cancer?. 2014 , 323-337		

57	Neoplastic Nodular T-Cell Pattern: An Approach to Diagnosis of Neoplastic Nodular T-Cell Lymphomas of the Skin. 2014 , 269-322		
56	Effects of Regulatory T CellDendritic Cell Interactions on Adaptive Immune Responses. 2014 , 21-27		
55	Dendritic Cell-Based Cancer Vaccines. 2014 , 69-87		
54	T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy. <i>Cancer Drug Discovery and Development</i> , 2015 , 211-229	0.3	
53	CAMPANELLI Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis. <i>European Endodontic Journal</i> , 2019 , 4, 3-8	1.5	1
52	Myeloid-Derived Suppressor Cells (MDSCs) in Aged Mice: Focus on Inflammation. 2019 , 711-731		
51	Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2020 , 3, 879-911	4.5	7
50	DNA vaccines for cervical cancer. <i>American Journal of Translational Research (discontinued)</i> , 2010 , 2, 75-83		16
49	T-cell Exhaustion and Cancer Immunotherapy. <i>Journal of International Oral Health</i> , 2015 , 7, i-ii	0.4	
48	[Programmed death ligand 1 negatively regulates inflammatory response of chronic periodontitis]. <i>Hua Xi Kou Qiang Yi Xue Za Zhi = Huaxi Kouqiang Yixue Zazhi = West China Journal of Stomatology</i> , 2015 , 33, 366-9		3
47	Astragalus polysaccharides reverse gefitinib resistance by inhibiting mesenchymal transformation in lung adenocarcinoma cells. <i>American Journal of Translational Research (discontinued)</i> , 2020 , 12, 1640-1657		
46	Degradation-resistant Implanted Biomaterials Establish an Immunosuppressive Microenvironment that Induces T Cell Exhaustion by Recruiting Myeloid Cells. <i>Fundamental Research</i> , 2021 ,		0
45	Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points. <i>Cancers</i> , 2021 , 13,	6.6	0
44	Soluble PD-L1 through alternative polyadenylation works as a decoy in lung cancer immunotherapy. <i>JCI Insight</i> , 2021 ,	9.9	1
43	CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma.. <i>Cancers</i> , 2022 , 14,	6.6	0
42	Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy.. <i>Japanese Journal of Radiology</i> , 2022 , 1	2.9	1
41	PD-L1 Expression Correlated with Clinicopathological Factors and Akt/Stat3 Pathway in Oral SCC.. <i>Life</i> , 2022 , 12,	3	1
40	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. <i>Journal of Biosciences</i> , 2020 , 45,	2.3	6

39	Glycans in Glycoimmunology. 2022 , 115-198		
38	Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression.. <i>Nature Communications</i> , 2022 , 13, 897	17.4	4
37	High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1 non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy.. <i>International Journal of Oncology</i> , 2022 , 60,	1	
36	Cancer therapy that targets the Hedgehog signaling pathway considering the cancer microenvironment (Review).. <i>Oncology Reports</i> , 2022 , 47,	3.5	1
35	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy.. <i>Life</i> , 2021 , 11,	3	1
34	Selective and Nongenetic Peroxidase Tag of Membrane Protein: a Nucleic Acid Tool for Proximity Labeling.. <i>Analytical Chemistry</i> , 2021 ,	7.8	0
33	Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	0
32	Data_Sheet_1.docx. 2018 ,		
31	Research progress of photothermal-mediated immunotherapy in the prevention of tumor recurrence and metastases. <i>Journal of Nanoparticle Research</i> , 2022 , 24,	2.3	0
30	Sensing Soluble Immune Checkpoint Molecules and Disease-Relevant Cytokines in Cancer: A Novel Paradigm in Disease Diagnosis and Monitoring. <i>Frontiers in Sensors</i> , 2022 , 3,	1.7	0
29	TERC suppresses PD-L1 expression by downregulating RNA binding protein HuR. <i>Science China Life Sciences</i> ,	8.5	
28	Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products. <i>Frontiers in Immunology</i> , 13,	8.4	0
27	A prodrug nanoplatfrom via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy. <i>Nano Research</i> ,	10	1
26	Potential of Black Phosphorus in Immune-Based Therapeutic Strategies. <i>Bioinorganic Chemistry and Applications</i> , 2022 , 2022, 1-18	4.2	
25	Therapeutic Applications of the CRISPR-Cas System. 2022 , 9, 477		0
24	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. 2022 , 73, 117001		2
23	Successes and failures of immunotherapy for gastric cancer. 2022 , 27, 103343		0
22	PD-1 blockage combined with vaccine therapy can facilitate immune infiltration in tumor microenvironment of Lynch syndrome colon cancer. 13,		0

21	Development of Surface Chemical Strategies for Synthesizing Redox-Responsive Diatomite Nanoparticles as a Green Platform for On-Demand Intracellular Release of an Antisense Peptide Nucleic Acid Anticancer Agent. 2204732	2
20	Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.	0
19	NOAEL Cancer Therapy: Tumor Targetable Docetaxel-Inorganic Polymer Nanohybrid Prevents Drug-Induced Neutropenia.	0
18	Targeted Molecular Therapy for Ovarian Cancer Patients. 2022 , 179-203	0
17	Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. 2022 , 10, e005573	1
16	Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer.	0
15	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. 2022 , 58, 1572	0
14	The emerging role of immunotherapy in the treatment of anal cancer. 2022 , 67, 102309	1
13	T-cell engaging poly(lactic-co-glycolic acid) nanoparticles as a modular platform to induce a potent cytotoxic immunogenic response against PD-L1 overexpressing cancer. 2022 , 291, 121911	0
12	Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis. 9,	0
11	Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese populationBased analysis. 13,	0
10	Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms.	0
9	Prognostic value of pretreatment immune inflammation indices in patients with immune-related tumors. 1-13	0
8	The exhaustion of lymphocytes is the main factor that decreases the sensitivity of QFT-GIT detection in silicosis. 2022 , 23,	0
7	Protein acylation: mechanisms, biological functions and therapeutic targets. 2022 , 7,	0
6	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. 2022 , 8,	0
5	T-Cell Metabolism and Its Regulation by Checkpoint Molecules: Consequences for Cancer Immunotherapy. 2023 , 1-20	0
4	Programmed Death-Ligand 1-Positive Squamous Cell Carcinoma Spontaneously Regressed after Percutaneous Needle Biopsy. 2023 , 59, 631	0

- 3 Recent Developments in Nanoparticle-Based Photo-Immunotherapy for Cancer Treatment. 2300252 ○
- 2 Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques. ○
- 1 Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy. **2023**, 150, 213425 ○